CP-481,715 Nickel Allergy Study.

Pfizer

Status and phase: Completed; Phase 1

Conditions: Dermatitis, Allergic Contact

Treatments: Drug: CP-481,715

Study type: Interventional

Funder types: Industry

Identifiers

NCT00141180

A3081018

Details and patient eligibility

About

To evaluate the suitability of contact allergy as a method for the evaluation of c-chemokine receptor-1 antagonist.

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A history of nickel allergy confirmed by a visual positive reaction (graded at least ++) to T.R.U.E. TEST.

Exclusion criteria

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding contact allergic dermatitis or untreated, asymptomatic, seasonal allergies at time of dosing).

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind